Scholarlink

Background <p>Ferroptosis, a form of programmed cell death, is a potential target for cancer therapy. Metazoan SpoT Homolog 1 (<i>MESH1</i>) possesses intracellular NADPH phosphatase activity, which has been linked to ferroptosis. However, the molecular effects on the ferroptosis in hepatocellular carcinoma (HCC) remain unclear. This study aimed to investigate the relationship between <i>MESH1</i> expression and the prognosis of patients with HCC, as well as its impact on ferroptosis in HCC cells.</p> Methods <p>We used resected specimens from patients to assess the relationship between <i>MESH1</i> expression and prognosis. HCC cell lines were used to evaluate the impact of <i>MESH1</i> expression on the cell phenotype and ferroptosis through various assays, RNA sequencing, and an animal experiment with xenograft mice model.</p> Results <p>We found that high <i>MESH1</i> expression correlated with good outcomes. Further investigation demonstrated that <i>MESH1</i> also exhibits NADPH phosphatase activity in HCC, contributing to increased sensitivity to ferroptosis when the ferroptosis inducer was used. Similar results were observed with other ferroptosis inducers, sorafenib and lenvatinib. Notably, RNA sequencing analysis of cells with <i>MESH1</i> KD revealed a correlation between intracellular iron homeostasis and <i>MESH1</i> levels. These results suggested that <i>MESH1</i> also can affect ferroptosis sensitivity through changing intracellular iron levels. Tumors derived from <i>MESH1</i> KD cells in xenograft mice showed reduced sensitivity to sorafenib and lenvatinib, further supporting the role of <i>MESH1</i> ferroptosis regulation.</p> Conclusion <p>This study suggests that <i>MESH1</i> influences intracellular redox and iron regulatory pathways, both of which are linked to cellular processes associated with ferroptosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Metazoan SpoT Homolog 1 promotes ferroptosis by regulating the intracellular redox cycle and iron levels in hepatocellular carcinoma

  • 期刊论文

  • 发表日期：

    2025年7月25日

查看全文
  • Yuki Nakayama,
  • Shinji Itoh,
  • Takeo Toshima,
  • Kyohei Yugawa,
  • Shohei Yoshiya,
  • Norifumi Iseda,
  • Yuriko Tsutsui,
  • Katsuya Toshida,
  • Takuma Ishikawa,
  • Tomoharu Yoshizumi

摘要

Background

Ferroptosis, a form of programmed cell death, is a potential target for cancer therapy. Metazoan SpoT Homolog 1 (MESH1) possesses intracellular NADPH phosphatase activity, which has been linked to ferroptosis. However, the molecular effects on the ferroptosis in hepatocellular carcinoma (HCC) remain unclear. This study aimed to investigate the relationship between MESH1 expression and the prognosis of patients with HCC, as well as its impact on ferroptosis in HCC cells.

Methods

We used resected specimens from patients to assess the relationship between MESH1 expression and prognosis. HCC cell lines were used to evaluate the impact of MESH1 expression on the cell phenotype and ferroptosis through various assays, RNA sequencing, and an animal experiment with xenograft mice model.

Results

We found that high MESH1 expression correlated with good outcomes. Further investigation demonstrated that MESH1 also exhibits NADPH phosphatase activity in HCC, contributing to increased sensitivity to ferroptosis when the ferroptosis inducer was used. Similar results were observed with other ferroptosis inducers, sorafenib and lenvatinib. Notably, RNA sequencing analysis of cells with MESH1 KD revealed a correlation between intracellular iron homeostasis and MESH1 levels. These results suggested that MESH1 also can affect ferroptosis sensitivity through changing intracellular iron levels. Tumors derived from MESH1 KD cells in xenograft mice showed reduced sensitivity to sorafenib and lenvatinib, further supporting the role of MESH1 ferroptosis regulation.

Conclusion

This study suggests that MESH1 influences intracellular redox and iron regulatory pathways, both of which are linked to cellular processes associated with ferroptosis.